Takeaway
Including autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) to standard of care (SOC) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) can provide a significant extension to overall survival (OS).
Why this matters?
Glioblastoma is an aggressive type of brain cancer that is associated with poor clinical outcomes.
New treatments that can extend OS are needed for patients with nGBM and rGBM.